DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA) CHANGES AND BODY MINERAL DENSITY IN PATIENT HAD SKELETAL COMPLICATION WITH RENAL FUNCTION IMPAIRMENT IN MOSUL
Keywords:
Kidney failure, bone mineral density, bone health, osteoporosis, x-ray absorptiometryAbstract
Kidney failure is one of the most common diseases worldwide, affecting almost all body systems and the kidneys in particular. This disorder primarily affects creatinine and urea levels, and can also directly affect bone health, so the relationship between kidney failure and bone mineral density has been an ongoing area of research, and early detection of low BMD in kidney failure patients helps prevent further bone loss. In this study, we can clarify some of the finer details, the main goal is to evaluate the effect of kidney failure on BMD among people in hospitals and clinics in Nineveh Governorate. They were divided into two groups, the first group was people with kidney failure, numbering 40, and the second group was healthy people, whose ages ranged from 18 to 73 years, while the ages of healthy people ranged from 31 to 80 years, and each group was divided into two subgroups, males and females. Osteoporosis was measured by a dual-energy device called (DEXA) and our study focused on the most important areas of the body to be examined, which are the spine and hip joint, which can provide valuable information about bone density. A significant decrease in BMD was observed in patients with renal failure and the prevalence of osteoporosis was higher, while the prevalence of osteoporosis among healthy individuals was much lower and the majority had normal bone density. Conclusion: The examination results showed a significant decrease in bone mineral content in patients with renal failure compared to healthy individuals in addition to a higher prevalence of osteoporosis in patients with renal failure, so it is necessary to take steps to support bone health. We recommend that patients with renal failure undergo a bone density test so that osteoporosis can be detected at the early stage itself and then receive appropriate preventive treatment.
References
1. Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, Prieto-Alhambra D, Torres PU, Cannata-Andia J (2021) Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 32:2397–2405 - PubMed - DOI
2. Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, Prieto-Alhambra D, Torres PU, Cannata-Andia J (2021) European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant 36:42–59 - PubMed - DOI
3. Neto R, Pereira L, Magalhães J, Quelhas-Santos J, Martins S, Carvalho C, Frazão JM (2021) Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4. Clin Kidney J
4. Sidibé A, Auguste D, Desbiens LC, Fortier C, Wang YP, Jean S, Moore L, Mac-Way F (2019) Fracture risk in dialysis and kidney transplanted patients: a systematic review. JBMR plus 3:45–55 - PubMed - DOI
5. Musgrove J, Wolf M (2020) Regulation and Effects of FGF23 in Chronic Kidney Disease. Annu Rev Physiol 82:365–390 - PubMed - DOI
6. Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH (2019) Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers. Clin Nephrol 91:222 - PubMed - PMC - DOI
7. Asadipooya K, Abdalbary M, Ahmad Y, Kakani E, Monier-Faugere MC, El-Husseini A (2021) Bone Quality in CKD Patients: Current Concepts and Future Directions – Part I. Kidney Dis 7:268–277 - DOI
8. Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int: J Established Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 30:3–44 - DOI
9. Lekamwasam S (2019) The diversity of Fracture Risk Assessment Tool (FRAX)-based intervention thresholds in Asia. Osteoporos Sarcopenia 5:104–108 - PubMed - PMC - DOI
10. Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, Collister D, Kanis JA, Tangri N (2019) The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int 95:447–454 - PubMed - DOI
11. Rampersad C, Whitlock RH, Leslie WD, Rigatto C, Komenda P, Bohm C, Hans D, Tangri N (2020) Trabecular bone score in patients with chronic kidney disease. Osteoporos Int: J Established Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 31:1905–1912 - DOI
12. Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC, Cooper C, Javaid K, Ferrari S, Akesson KE (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32:399–411 - PubMed - PMC - DOI
13. Tridimas A, Milan A, Marks E (2021) Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference. Ann Clin Biochem 45632211025567
14. Laowalert S, Khotavivattana T, Wattanachanya L, Luangjarmekorn P, Udomkarnjananun S, Katavetin P, Eiam-Ong S, Praditpornsilpa K, Susantitaphong P (2020) Bone turnover markers predict type of bone histomorphometry and bone mineral density in Asian chronic haemodialysis patients. Nephrology (Carlton) 25:163–171 - DOI
15. Jørgensen HS, Behets G, Viaene L et al (2021) Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. Am J Kidney Dis
16. Schoeb M, Hamdy NAT, Malgo F, Winter EM, Appelman-Dijkstra NM (2020) Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature. Front Endocrinol (Lausanne) 11:15 - DOI
17. Holloway-Kew KL, Rufus-Membere P, Anderson KB, Betson A, Gaston J, Kotowicz MA, Diez-Perez A, Hyde NK, Pasco JA (2020) Bone material strength index is associated with prior fracture in men with and without moderate chronic kidney disease. Bone 133:115241 - PubMed - DOI
18. Asadipooya K, Abdalbary M, Ahmad Y, Kakani E, Monier-Faugere M-C, El-Husseini A (2021) Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions–Part II. Kidney Dis 1–13
19. Rysz J, Franczyk B, Rokicki R, Gluba-Brzózka A (2021) The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Nutrients 13:
20. Cardoso DF, Marques EA, Leal DV, Ferreira A, Baker LA, Smith AC, Viana JL (2020) Impact of physical activity and exercise on bone health in patients with chronic kidney disease: a systematic review of observational and experimental studies. BMC Nephrol 21:334–334 - PubMed - PMC - DOI
21. Yuan S, Michaëlsson K, Wan Z, Larsson SC (2019) Associations of Smoking and Alcohol and Coffee Intake with Fracture and Bone Mineral Density: A Mendelian Randomization Study. Calcif Tissue Int 105:582–588 - PubMed - DOI
22. Kunizawa K, Hiramatsu R, Hoshino J et al (2020) Denosumab for dialysis patients with osteoporosis: A cohort study. Sci Rep 10:2496 - PubMed - PMC - DOI